scholarly journals The Effects of Time-Restricted Eating versus Standard Dietary Advice on Weight, Metabolic Health and the Consumption of Processed Food: A Pragmatic Randomised Controlled Trial in Community-Based Adults

Nutrients ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 1042
Author(s):  
Nicholas Phillips ◽  
Julie Mareschal ◽  
Nathalie Schwab ◽  
Emily Manoogian ◽  
Sylvie Borloz ◽  
...  
Keyword(s):  
Weight Loss ◽  
Randomised Controlled Trial ◽  
Controlled Trial ◽  
Smartphone Application ◽  
Metabolic Health ◽  
Dietary Advice ◽  
Processed Food ◽  
Significant Difference ◽  
Randomised Controlled ◽  
Pragmatic Randomised Controlled Trial

Weight loss is key to controlling the increasing prevalence of metabolic syndrome (MS) and its components, i.e., central obesity, hypertension, prediabetes and dyslipidaemia. The goals of our study were two-fold. First, we characterised the relationships between eating duration, unprocessed and processed food consumption and metabolic health. During 4 weeks of observation, 213 adults used a smartphone application to record food and drink consumption, which was annotated for food processing levels following the NOVA classification. Low consumption of unprocessed food and low physical activity showed significant associations with multiple MS components. Second, in a pragmatic randomised controlled trial, we compared the metabolic benefits of 12 h time-restricted eating (TRE) to standard dietary advice (SDA) in 54 adults with an eating duration > 14 h and at least one MS component. After 6 months, those randomised to TRE lost 1.6% of initial body weight (SD 2.9, p = 0.01), compared to the absence of weight loss with SDA (−1.1%, SD 3.5, p = 0.19). There was no significant difference in weight loss between TRE and SDA (between-group difference −0.88%, 95% confidence interval −3.1 to 1.3, p = 0.43). Our results show the potential of smartphone records to predict metabolic health and highlight that further research is needed to improve individual responses to TRE such as a shorter eating window or its actual clock time.

scholarly journals The effects of time-restricted eating vs. standard dietary advice on weight, metabolic health and the consumption of processed food: A pragmatic randomised controlled trial in community-based adults

2021 ◽  
Author(s):  
Nicholas Edward Phillips ◽  
Julie Mareschal ◽  
Nathalie Schwab ◽  
Emily N.C. Manoogian ◽  
Sylvie Borloz ◽  
...  
Keyword(s):  
Weight Loss ◽  
Randomised Controlled Trial ◽  
Controlled Trial ◽  
Metabolic Health ◽  
Dietary Advice ◽  
Individual Response ◽  
Processed Food ◽  
Significant Difference ◽  
Randomised Controlled ◽  
Pragmatic Randomised Controlled Trial

AbstractThe prevalence of metabolic syndrome (MS) is increasing, affecting approximately 1 billion people. Weight loss is key to control MS components, i.e. central obesity, hypertension, prediabetes, and dyslipidaemia. Here, we characterised the relationships between eating duration, unprocessed and processed food consumption, and metabolic health. In a 4-week observation phase, 213 Swiss adults recorded consumed meals and drinks with a smartphone application, and these were annotated for food processing levels according to the NOVA classification. Regression analysis showed that consumption of unprocessed food items showed the highest number of significant relationships with MS components after age and sex. The fraction of unprocessed food out of all ingestion events was positively associated with HDL cholesterol and negatively associated with BMI, waist circumference and triglycerides. Next, in a pragmatic randomised controlled trial, we tested whether 12h time-restricted eating (TRE) leads to metabolic benefits compared to standard dietary advice (SDA), in 54 adults who ate >14h per 24h cycle and had at least one MS component. After 6 months, those randomised to TRE lost 1.6% of initial body weight (SD 2.9, p = 0.01), compared to the absence of weight loss with SDA (−1.1%, SD 3.5, p = 0.19). Thus, there was no significant difference in weight loss between TRE and SDA (between-group difference −0.5 kg, 95% confidence interval −2.4 to 1.4, p = 0.61). Overall, our results show the potential of smartphone records to predict metabolic health, and highlight that further research is needed to understand individual response to TRE and SDA.

Acupuncture Combined with An Antidepressant for Patients with Depression in Hospital: A Pragmatic Randomised Controlled Trial

2014 ◽  
Vol 32 (4) ◽  
pp. 308-312 ◽  
Author(s):  
Tianjun Wang ◽  
Lingling Wang ◽  
Wenjian Tao ◽  
Li Chen
Keyword(s):  
Randomised Controlled Trial ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Rating Scale ◽  
Controlled Trial ◽  
Control Groups ◽  
Significant Difference ◽  
The Mean ◽  
Randomised Controlled ◽  
And Control ◽  
Pragmatic Randomised Controlled Trial

Objective To assess the effectiveness of acupuncture combined with selective serotonin reuptake inhibitors (SSRIs) for patients with depression in hospital using a pragmatic randomised controlled trial. Methods 76 patients with depression were randomly divided into two groups (randomisation ratio 2:1 for treatment and control groups (CGs), respectively) and 71 patients completed the study. The 45 patients in the treatment group (TG) underwent acupuncture and received an SSRI and the 26 patients in the CG received an SSRI only. The 17-item Hamilton Depression Rating Scale (HDRS-17) was used to quantitatively assess patients after 1, 2, 4 and 6 weeks of treatment. Results The mean (SD) baseline total HDRS scores were 22.2 (0.60) and 22.1 (0.33) in the TG and CG, respectively. After the first week of treatment the HDRS score for the TG was reduced to 15.6 (0.81), significantly different from the score of 18.3 (0.55) for the CG, p<0.05. This significant difference was maintained to the end of the 6-week treatment period, when HDRS scores had fallen to 6.3 (0.49) and 8.2 (0.35) for the TG and CG, respectively. Conclusions Acupuncture combined with an SSRI showed a statistically significant benefit for patients with depression in hospital over the 6-week period compared with SSRIs alone. This reduction in symptoms started in the first week and continued throughout the 6 weeks of treatment.

Revolutionising participants’ health and wellbeing through neuro-reprogramming via the Slimpod® app: a randomised controlled trial

2020 ◽  
Vol 70 (suppl 1) ◽  
pp. bjgp20X711701
Author(s):  
Richard Kyle ◽  
Stephen Jones ◽  
Sandra Roycroft-Davis
Keyword(s):  
Weight Loss ◽  
Randomised Controlled Trial ◽  
Weight Management ◽  
Self Efficacy ◽  
Controlled Trial ◽  
Intervention Group ◽  
Eating Behaviours ◽  
Significant Difference ◽  
Randomised Controlled ◽  
Overweight Adults

BackgroundObesity is a global pandemic that threatens the health of the population and the sustainability of publicly funded health care. This randomised controlled trial addresses the gap in the literature surrounding unconscious persuasion and its use in weight loss and weight management. The Slimpod® tool is unlike any of those currently available on the market. Using breakthrough research in ‘nudge’ thinking, it is designed to retrain an adult’s habitual and emotional response to foodstuffs. This therapeutic model allows unconscious thought to be shaped into a manner more consistent with a healthy lifestyle. Candidates can then take control of their eating behaviours to induce a holistic state of wellbeing.AimTo assess the effectiveness of an audio unconscious-persuasion weight loss/weight management intervention (Slimpod®) compared with audio relaxation (control).MethodEighty-two overweight adults were randomised to intervention (n = 41) and control groups (n = 41). Weight was assessed at trial commencement, mid-trial (12 weeks), and trial end (24 weeks). Secondary outcomes were assessed using the Eating Self-Efficacy Scale (ESES), Exercise Confidence Scale (ECS), and Quality of Life Index Generic Version III (QLI-G3) at the start and end of the trial.ResultsReports found a statistically significant difference in mean weight loss between intervention group (1.7 kg at 12 weeks and 4.3 kg at 24 weeks) versus control (0.6 kg and 1.2 kg respectively) at P<0.001. ESES scores showed greater self-efficacy (P = 0.008) in intervention at 24 weeks. No significant differences in ESES negative affect sub-scale score or ECS were observed.ConclusionSlimpod® was effective at reducing weight and increasing eating self-efficacy in overweight adults.

scholarly journals Smart Phone APP to Restore Optimal Weight (SPAROW): protocol for a randomised controlled trial for women with recent gestational diabetes

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Karen Lim ◽  
Claudia Chi ◽  
Shiao-Yng Chan ◽  
Su Lin Lim ◽  
Siew Min Ang ◽  
...  
Keyword(s):  
Weight Loss ◽  
Randomised Controlled Trial ◽  
Gestational Diabetes ◽  
Controlled Trial ◽  
Smartphone Application ◽  
Healthy Weight ◽  
Optimal Weight ◽  
Increased Risk ◽  
Postpartum Weight ◽  
Randomised Controlled

Abstract Background Gestational diabetes (GDM) is a known risk factor for type 2 diabetes mellitus (T2DM), and women with a history of GDM have a 7-fold increased risk of developing the disease. Achieving a healthy weight post-delivery is key in reducing the risk of future diabetes in these women. The aim of this trial is to investigate the use of an interactive smartphone application (APP) to restore women to optimal weight following delivery. Methods This will be an open-label randomized controlled trial. Two hundred women with gestational diabetes will be randomized to receive the intervention or standard care following delivery. Participants will be reviewed at 6 weeks and 4 months post-delivery. The intervention is an APP serving as a platform for weight, diet and physical activity tracking. The APP provides 3–5 min educational videos suggesting suitable lifestyle adjustments relevant to postnatal period such as breast feeding, diet and exercise. Lastly, the APP will allow real-time interaction between users and the team of dietitians, physiotherapists and occupational therapists to encourage restoration of optimal weight. Women in the control arm will be informed about the increased risk of developing T2DM and advised to maintain a healthy weight. Primary outcome measure is the restoration of participants’ booking weight if booking BMI ≤ 23, or weight loss of at least 5% from booking weight if booking BMI > 23 over the 4 month period. Secondary outcome measures will assess serum metabolic and inflammatory markers, quality of life via questionnaires and cost-effectiveness of the intervention at each follow-up visit. Discussion This will be the first randomised controlled trial investigating the use of a smartphone application for postpartum weight loss in women with gestational diabetes. The major ethnic groups in our study population represent the majority of ethnic groups in Asia, amongst which the prevalence of diabetes is high. If shown to be effective, this APP may be used in wider clinical settings to improve postpartum weight loss and reduce the risk of developing T2DM in these women. Trial registration This study was registered on clintrials.gov on the 30th of October 2017, under the trial registration number: NCT03324737.

scholarly journals A pragmatic randomised controlled trial in primary care of the Camden Weight Loss (CAMWEL) programme

BMJ Open ◽  
2012 ◽  
Vol 2 (3) ◽  
pp. e000793 ◽  
Author(s):  
Kiran Nanchahal ◽  
Tom Power ◽  
Elizabeth Holdsworth ◽  
Michelle Hession ◽  
Annik Sorhaindo ◽  
...  
Keyword(s):  
Primary Care ◽  
Weight Loss ◽  
Randomised Controlled Trial ◽  
Controlled Trial ◽  
Randomised Controlled ◽  
Pragmatic Randomised Controlled Trial
Sign in / Sign up

Export Citation Format

Share Document